The US FDA may be softening its rhetoric on the administration's proposal to adjust the 180-day exclusivity clock for first generics, in addition to downplaying its potential impact to a nervous industry.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?